Testing pembrolizumab plus chemotherapy for aggressive metastatic prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 trial tests pembrolizumab together with carboplatin and cabazitaxel in men with aggressive, metastatic prostate cancer that has become resistant to hormone therapy. It may help shrink tumors and improve outcomes for people with hard-to-treat forms of prostate cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a man age 18 or older and be willing to sign the study consent form
- Have prostate cancer confirmed by tissue testing (adenocarcinoma and/or neuroendocrine/small cell type)
- Have cancer that has spread to other parts of the body, confirmed on scans (bone scan, CT, and/or MRI)
- Have aggressive prostate cancer features (for example, small cell type, certain high-risk metastasis patterns, or fast progression after hormone treatment)
- Not have received certain past treatments: no prior pembrolizumab/PD-1/PD-L1/PD-L2, no prior carboplatin or cabazitaxel, and no cancer therapy within 4 weeks
- Be well enough to participate (good functional status) and have recent tumor tissue available for lab testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
This early-phase trial tests pembrolizumab (an immune therapy) plus an androgen-receptor–blocking prostate cancer drug, and possibly a targeted radiation treatment. It’s for men with prostate cancer that has spread and keeps worsening despite standard hormone therapy, aiming to shrink tumors and improve control of the disease.
This study combines two treatments: pembrolizumab, which helps your immune system fight cancer, and a targeted radioactive medicine (177Lu-PSMA-617) that seeks out and damages prostate cancer cells. It may help men whose prostate cancer has spread despite initial hormone therapy.
This study tests a combination of three drugs—ADI-PEG20, carboplatin, and cabazitaxel—in men with aggressive variant prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination can shrink or slow the cancer.
This study tests whether adding a chemotherapy drug called carboplatin to another chemotherapy called cabazitaxel works better than cabazitaxel alone for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. All participants must have already had docetaxel chemotherapy.
This Phase 2 trial studies whether pembrolizumab plus a hormone “androgen axis” blocker taken before prostate surgery can improve outcomes for people with high-risk, non-metastatic prostate cancer. It’s designed for patients who are planning prostate removal with an extended lymph node dissection.
Hear when a new Prostate Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.